8-K: Castle Biosciences Q2 2026 Earnings: Revenue Up, Guidance Raised

Castle Biosciences reported strong second quarter 2026 results, with revenue increasing to $103.5 million and full-year revenue guidance raised to $365-375 million.

Summary

• Castle Biosciences announced its financial results for the second quarter ended June 30, 2026.
• Total revenue for Q2 2026 was $103.5 million, an increase from $86.2 million in Q2 2025.
• Core revenue drivers, DecisionDx-Melanoma and TissueCypher, saw a 32% increase in total test reports compared to Q2 2025.
• The company is raising its full-year 2026 revenue guidance to $365-375 million, up from $345-355 million.
• Castle Biosciences now expects to achieve positive Adjusted EBITDA for the third quarter, fourth quarter, and full year 2026.
• Net loss for Q2 2026 was $2.1 million, compared to a net income of $4.5 million in Q2 2025.
• Adjusted EBITDA for Q2 2026 was $12.4 million, an increase from $10.4 million in Q2 2025.
• Cash, cash equivalents, and marketable investment securities totaled $266.8 million as of June 30, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, driven by strong revenue growth, raised guidance, and improved profitability outlook, despite a net loss in the quarter.

Positives

• Revenue increased by 19.9% to $103.5 million in Q2 2026 compared to $86.2 million in Q2 2025.
• Full-year 2026 revenue guidance has been raised to $365-375 million from $345-355 million.
• Positive Adjusted EBITDA is now expected for Q3, Q4, and the full year 2026.
• Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased by 32% year-over-year in Q2 2026.
• DecisionDx-Melanoma test reports increased to 10,280 from 9,981 in Q2 2025.
• TissueCypher Barretts Esophagus test reports significantly increased to 14,988 from 9,170 in Q2 2025.
• Adjusted EBITDA increased to $12.4 million in Q2 2026 from $10.4 million in Q2 2025.
• The company maintains a strong cash position of $266.8 million as of June 30, 2026.

Negatives

• Net loss for Q2 2026 was $2.1 million, a decrease from a net income of $4.5 million in Q2 2025.
• Net loss per share was $0.07 in Q2 2026, compared to net income per share of $0.16 in Q2 2025.
• Gross margin was 75% in Q2 2026, down from 77% in Q2 2025.
• Adjusted Gross Margin decreased to 76% in Q2 2026 from 80% in Q2 2025.
• Net cash provided by operations was $15.2 million in Q2 2026, a decrease from $20.8 million in Q2 2025.
• For the six months ended June 30, 2026, net loss was $16.6 million, compared to a net loss of $21.3 million in the prior year period.
• Adjusted EBITDA for the six months ended June 30, 2026, was $7.3 million, a significant decrease from $23.4 million in the prior year period.
• Net cash used in operations for the six months ended June 30, 2026, was $6.9 million, compared to net cash provided by operations of $14.8 million in the prior year period.

Risks

• The change in DecisionDx-SCC Medicare coverage effective April 24, 2025, has affected revenue.
• The discontinuation of IDgenetix in May 2025 impacted revenue comparisons.
• The company faces risks related to reimbursement for its products and subsequent coverage decisions.
• Macroeconomic events and conditions, including inflation, labor shortages, and geopolitical events, could impact the business.
• Subsequent study or trial results may contradict earlier findings or not support the results discussed.
• The company's newer gastroenterology and mental health franchises may not contribute to long-term financial targets as anticipated.
• Risks associated with the development and commercialization of new tests.
• Potential need for additional financing.

Future Outlook

The company is raising its full-year 2026 total revenue guidance to $365-375 million. Additionally, Castle Biosciences expects to achieve positive Adjusted EBITDA for the third quarter, fourth quarter, and the full year 2026. The company anticipates continued top-line performance and growth of test volumes, with a focus on driving adoption of its tests and advancing its pipeline initiatives.

Management Comments

• "The Castle Biosciences team delivered another outstanding quarter," said Derek Maetzold, president and chief executive officer.
• "We believe our strong growth through the first half of 2026 demonstrates the clinical value our tests bring to patient care and the dedication of our talented team to deliver results so that our clinician customers and patients can act with confidence."
• "Given this momentum, we are raising our 2026 total revenue guidance to $365-375 million, up from our previous range of $345-355 million."
• "We also now expect to achieve positive Adjusted EBITDA for the third quarter, the fourth quarter and the full year 2026."
• "I want to thank the entire Castle team for their focus, commitment and disciplined execution, which continue to advance our mission of improving health through innovative tests that guide patient care."

Industry Context

StockSavvy.ai notes that Castle Biosciences' performance in Q2 2026, particularly the increase in core test volumes and raised revenue guidance, aligns with the growing demand for precision diagnostics in healthcare. The company's focus on developing and validating innovative tests for conditions like melanoma and atopic dermatitis positions it within a key growth area of the diagnostics market.

Comparison to Industry Standards

• The 32% year-over-year increase in test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) in Q2 2026 significantly outpaces the typical growth rates seen in the broader molecular diagnostics market, which often experiences single-digit or low double-digit growth.
• The company's raised full-year revenue guidance of $365-375 million suggests a robust growth trajectory that is competitive within the specialized diagnostics sector.
• The achievement of positive Adjusted EBITDA in Q3, Q4, and full-year 2026, if realized, would demonstrate strong operational efficiency and profitability, a key benchmark for sustainable growth in the healthcare technology industry.
• The 76.3% Adjusted Gross Margin for Q2 2026 is a strong indicator of efficient operations and pricing power, often exceeding industry averages for companies with similar product development and manufacturing costs.

Stakeholder Impact

• Shareholders: Potential for increased value due to raised revenue guidance and improved profitability outlook.
• Clinicians: Continued access to innovative tests that guide patient care and treatment decisions.
• Patients: Benefit from more informed treatment planning and potentially improved outcomes due to the clinical utility of Castle's tests.
• Payers: Continued engagement on the clinical and economic value of the company's diagnostic solutions.

Next Steps

• Continue to drive test volume growth.
• Maintain strong Adjusted Gross Margin.
• Maintain a strong balance sheet.
• Follow a disciplined capital allocation strategy.
• Achieve near-term Adjusted EBITDA positivity.
• Advance pipeline opportunities.
• Continue to build evidentiary support for tests.
• Develop new tests.

Key Dates

Recommendation

The company demonstrated strong Q2 2026 performance with significant revenue growth, a raised full-year guidance, and a positive outlook for Adjusted EBITDA. The substantial increase in core test volumes and the strategic advancements in their product portfolio, particularly AdvanceAD-Tx, indicate robust market traction and future growth potential. Despite a quarterly net loss, the overall financial health and strategic direction suggest a compelling investment opportunity.

Keywords

Castle Biosciences, Q2 2026 Earnings, Revenue Guidance, Adjusted EBITDA, DecisionDx-Melanoma, TissueCypher, AdvanceAD-Tx, Genomic Tests